A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
for Carcinoma, Non-Small-Cell Lung
25 locations incl. Birmingham
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Sex: All·Age: 18+
Code: NCT05208762·Phase 1·Recruiting·Listed Jan 2022
UT Southwestern/Simmons Cancer Center-Fort Worth
Clinical research site in Fort Worth, Texas
Part of UT Southwestern Medical Center
As of July 2026, 26 paid clinical trials are recruiting at UT Southwestern/Simmons Cancer Center-Fort Worth in Fort Worth, Texas. Active studies at this site cover conditions such as Stage IVB Prostate Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8 and Metastatic Renal Cell Carcinoma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Recruiting clinical trials at UT Southwestern/Simmons Cancer Center-Fort Worth (26)
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
for Stage III Colon Cancer
922 locations incl. Fairhope
Sponsor: NRG Oncology
Sex: All·Age: 18+
Code: NCT05174169·Phase 2, Phase 3·Recruiting·Listed Dec 2021
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
for Locally Advanced Cervical Adenocarcinoma
289 locations incl. Birmingham
Sponsor: National Cancer Institute (NCI)
Sex: Female·Age: 18+
Code: NCT07061977·Phase 3·Recruiting·Listed Jul 2025
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
for Anatomic Stage II Breast Cancer AJCC v8
776 locations incl. Fairhope
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 18+
Code: NCT05812807·Phase 3·Recruiting·Listed Apr 2023
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
for Advanced Esophageal Adenocarcinoma
643 locations incl. Anchorage
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 18+
Code: NCT05677490·Phase 3·Recruiting·Listed Jan 2023
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
for Smoldering Plasma Cell Myeloma
488 locations incl. Birmingham
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All·Age: 18+
Code: NCT03937635·Phase 3·Recruiting·Listed May 2019
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
for Muscle Invasive Bladder Urothelial Carcinoma
449 locations incl. Phoenix
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT05987241·Phase 2, Phase 3·Recruiting·Listed Aug 2023
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
for Pancreatic Acinar Cell Carcinoma
261 locations incl. Kingman
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT04858334·Phase 2·Recruiting·Listed Apr 2021
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
for Bladder Adenocarcinoma
224 locations incl. Phoenix
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT03866382·Phase 2·Recruiting·Listed Mar 2019
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
for Clear Cell Renal Cell Carcinoma
405 locations incl. Phoenix
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 18+
Code: NCT06661720·Phase 3·Recruiting·Listed Oct 2024
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
for Advanced Lung Non-Small Cell Carcinoma
266 locations incl. Fayetteville
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 70+
Code: NCT06096844·Phase 3·Recruiting·Listed Oct 2023
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
for Biochemically Recurrent Prostate Carcinoma
278 locations incl. Anchorage
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: Male·Age: 18+
Code: NCT04423211·Phase 3·Recruiting·Listed Jun 2020
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
for Metastatic Renal Cell Carcinoma
280 locations incl. Kingman
Sponsor: NRG Oncology
Sex: All·Age: 18+
Code: NCT05327686·Phase 2·Recruiting·Listed Apr 2022
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
for Renal Pelvis and Ureter Urothelial Carcinoma
152 locations incl. Kingman
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT04628767·Phase 2, Phase 3·Recruiting·Listed Nov 2020
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
for Muscle Invasive Bladder Urothelial Carcinoma
148 locations incl. Birmingham
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT07061964·Phase 2·Recruiting·Listed Jul 2025
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
for Castration-Sensitive Prostate Carcinoma
190 locations incl. Tucson
Sponsor: Alliance for Clinical Trials in Oncology
Sex: Male·Age: 18+
Code: NCT06931340·Phase 3·Recruiting·Listed Apr 2025
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
for Endometrial Adenocarcinoma
126 locations incl. Birmingham
Sponsor: National Cancer Institute (NCI)
Sex: Female·Age: 18+
Code: NCT05112601·Phase 2·Recruiting·Listed Nov 2021
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
for Pleural Biphasic Mesothelioma
111 locations incl. Anchorage
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 18+
Code: NCT05647265·Phase 2·Recruiting·Listed Dec 2022
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
for Castration-Resistant Prostate Carcinoma
102 locations incl. Birmingham
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 18+
Code: NCT06632977·Phase 2·Recruiting·Listed Oct 2024
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
for Fallopian Tube Endometrioid Adenocarcinoma
645 locations incl. Birmingham
Sponsor: NRG Oncology
Sex: All·Age: 18+
Code: NCT06580314·Phase 3·Recruiting·Listed Aug 2024
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
for Metastatic Colorectal Carcinoma
58 locations incl. Gilbert
Sponsor: ECOG-ACRIN Cancer Research Group
Sex: All·Age: 18+
Code: NCT05863195·Phase 3·Recruiting·Listed May 2023
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
for Autoimmune Disease
41 locations incl. Sacramento
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT03816345·Phase 1·Recruiting·Listed Jan 2019
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
for Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
41 locations incl. Coral Gables
Sponsor: NRG Oncology
Sex: Female·Age: 18+
Code: NCT05646316·Phase 3·Recruiting·Listed Dec 2022
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
for Cardiotoxicity
144 locations incl. Duarte
Sponsor: SWOG Cancer Research Network
Sex: All·Age: 18+
Code: NCT03418961·Phase 3·Recruiting·Listed Feb 2018
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
for Metastatic Clear Cell Renal Cell Carcinoma
340 locations incl. Birmingham
Sponsor: SWOG Cancer Research Network
Sex: All·Age: 18+
Code: NCT04510597·Phase 3·Recruiting·Listed Aug 2020
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
for Castration Levels of Testosterone
294 locations incl. Gilbert
Sponsor: SWOG Cancer Research Network
Sex: Male·Age: 18+
Code: NCT03678025·Phase 3·Recruiting·Listed Sep 2018
More research sites in Fort Worth
- Cook Children's Medical Center (56 trials)
- Cook Children's Health Care System (11 trials)
- Re:Cognition Health - Fort Worth (8 trials)
- Cook Children's Hospital (6 trials)
- JPS Health Network (6 trials)
- Texas Christian University (5 trials)
- Baylor All Saints Medical Center (4 trials)
- GI Alliance - Fort Worth (4 trials)
- John Peter Smith Hospital (4 trials)
- START Dallas (4 trials)
Explore more
Paid clinical trials in Fort Worth, TX · Texas clinical trials